(Q53254550)

12 May 2018

title

Prognostic relevance of biological subtype overrides that of TNM staging in breast cancer: discordance between stage and biology. (English)

1 reference

12 May 2018

author name string

Hyun Ae Jung

1

1 reference

12 May 2018

Yeon Hee Park

2

1 reference

12 May 2018

Moonjin Kim

3

1 reference

12 May 2018

Sungmin Kim

4

1 reference

12 May 2018

Won Jin Chang

5

1 reference

12 May 2018

Moon Ki Choi

6

1 reference

12 May 2018

Jung Yong Hong

7

1 reference

12 May 2018

Seok Won Kim

8

1 reference

12 May 2018

Won Ho Kil

9

1 reference

12 May 2018

Jeong Eon Lee

10

1 reference

12 May 2018

Seok Jin Nam

11

1 reference

12 May 2018

Jin Seok Ahn

12

1 reference

12 May 2018

Young-Hyuck Im

13

1 reference

12 May 2018

publication date

19 October 2014

1 reference

12 May 2018

published in

Tumor Biology

1 reference

12 May 2018

volume

36

1 reference

12 May 2018

issue

2

1 reference

12 May 2018

page(s)

1073-1079

1 reference

12 May 2018

Luminal breast cancer classification according to proliferative indices: clinicopathological characteristics and short-term survival analysis.

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2730-2

Studies of the HER-2/neu proto-oncogene in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2730-2

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2730-2

Pattern of metastatic spread in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2730-2

Triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2730-2

Potential impact of the 70-gene signature in the choice of adjuvant systemic treatment for ER positive, HER2 negative tumors: a single institution experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2730-2

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2730-2

Triple-negative breast cancer: therapeutic options

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2730-2

Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2730-2

Prognostic value of positive human epidermal growth factor receptor 2 status and negative hormone status in patients with T1a/T1b, lymph node-negative breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2730-2

Clinical relevance of TNM staging system according to breast cancer subtypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2730-2

The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2730-2

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2730-2

The MINDACT trial: the first prospective clinical validation of a genomic tool

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2730-2

Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2730-2

Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2730-2

High fasting blood glucose and obesity significantly and independently increase risk of breast cancer death in hormone receptor-positive disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2730-2

Small node-negative (T1b-cN0) invasive hormone receptor-positive breast cancers: is there a subpopulation that might have benefit from adjuvant chemotherapy?

21 January 2018

1 reference

12 December 2020

HORMONE dependence and breast cancer

1 reference

12 December 2020

TAILORx: trial assigning individualized options for treatment (Rx)

1 reference

12 December 2020

Prognostic and predictive factors in breast cancer by immunohistochemical analysis.

1 reference

12 December 2020

Clinicopathologic features of molecular subtypes of triple negative breast cancer based on immunohistochemical markers

1 reference

12 December 2020

10.1007/S13277-014-2730-2

Identifiers

DOI

1 reference

12 May 2018

1 reference

12 May 2018